Navigation Links
ChanTest Announces ChansPorter™ Assays to Accelerate Drug Development for Cystic Fibrosis Patients
Date:7/18/2013

Cleveland, OH (PRWEB) July 18, 2013

The new ChansPorter™ Assays provide faster and more accurate answers. Using human (patient-derived) bronchial epithelia, and incorporating higher throughput into the discovery screening and profiling processes increases productivity several fold by eliminating false positives and negatives arising from animal cell lines. Time-to-results also is shortened significantly, saving time and cost.

In a Cystic Fibrosis (CF) patient, the CF gene tells the individual’s epithelial cells to produce a defective version of the CFTR protein, which causes the mucus that lines the lungs (and other organs) to become thickened and sticky. Impaired epithelial transport function results in chronic disease that reduces quality of life and life expectancy.

In the process of drug discovery, a better understanding of the function of a target protein like CFTR in disease leads to the development of better drug candidates. When considering epithelial diseases like CF, functional assays for measuring drug effects on the activity of electrogenic transporters (that mediate fluid transport or flow) play an important role.

The Ussing Chamber Assay (UCA) is an established electrophysiological assay that uses epithelial voltage clamp technology to evaluate electrogenic transporter activity and measure net fluid transport, electrolyte, nutrient and drug transport across epithelial tissues. The UCA has been used to measure ex vivo (tissue) transport activity in essentially all epithelia. Cultured epithelial cells (primary and cell lines) capable of forming polarized epithelia (epithelia which allow the tissue to secrete or absorb fluid) are used extensively in in vitro UCAs for functional evaluations in drug discovery, physiology and toxicology.

“We have a highly-skilled team of cell biologists and electrophysiologists at ChanTest working on the Ussing Assay for drug discovery clients,” said Dr. Antonio Lacerda, Director of Contract Research & Development Services at ChanTest. “Now, building on this technology, with ChansPorter Assays, I believe that we have the highest throughput in the industry, and a strong, high-quality capability for measuring important epithelial targets, such as CFTR.”

ChanTest regularly performs high-quality experiments on an unprecedented scale. ChansPorter Assays include three independent 24-chamber Ussing systems dedicated to CF, R&D and contract research testing with the capacity to simultaneously test 72 epithelia grown on SnapWell™ filter inserts. A fourth 24-chamber system is used for cGMP compliant release assays.

ChanTest employs a higher throughput embodiment of the UCA with a semi-automated system that utilizes a robot, a 24-channel epithelial voltage clamp (TECC-24) and 24-well microplates containing CFhBE (Cystic Fibrosis human Bronchial Epithelia) grown on permeable support for up to five times the throughput of the 24-chamber systems. The epithelia are derived from cultures of patient primary cells or cell lines (of both human and animal origin).

There is an urgent need to accelerate the identification of new solutions in drug discovery for cystic fibrosis patients. ChansPorter™ Assays provide the industry with a way to more quickly and accurately assess the best drug candidates by measuring the functional activity of important pharmaceutical targets, including CFTR.

To learn more about the ChanTest® ChansPorter™ Assays, click here.

About ChanTest® – The Ion Channel Expert

ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high value solutions for ion channel and GPCR biology. Since its inception in 1998, the CRO has tested compounds for more than 300 global pharmaceutical and biotechnology companies, and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines, and nonclinical cardiac risk assessment service portfolio, is the most comprehensive commercially available today. Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for service provider” for ion channel screening in an independent survey since 2006. ChanTest is based in Cleveland, Ohio.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10937160.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New hCG Diet Plans, a Fool-Proof Fast Weight Loss Method to Naturally Trim the Waistline
2. Powered by Shopping Cart Elite, Isatori.com Announces New Products and Deals for the Season
3. Magnetic Ankle Bracelet Relieves Pain in Seconds, Announces Pain Free Living
4. Special Learning, Inc. Announces New Social Story App for iPad
5. TrustedConsumerReview Announces Best NJ Bankruptcy Lawyer
6. TrustedConsumerReview Announces Best Truck Springs Retailer
7. truDERMA® Announces Product Distribution into Select Bally Total Fitness Locations
8. Superior Van & Mobility Announces Participation in the "My Finish Line" Movie and Music Tour at their Evansville, Indiana location July 30th from 2 to 5 p.m.
9. Intentional Living Center Store Announces a Summer Sale
10. DXE Medical, Inc. Announces Customer Specials for Zoll Defibrillators
11. IEEE Engineering in Medicine and Biology Society Announces the Launch of the Journal of Translational Engineering in Health and Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... ... ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with machine ... IT system, from the datacenter to the cloud to the edge. Through the ...
(Date:5/24/2017)... Massapequa Park, NY (PRWEB) , ... May 24, ... ... today announced the practice is offering holistic pediatric dentistry options for its patients ... the context of the patient’s entire physical well being, and is one of ...
(Date:5/24/2017)... Chicago, IL (PRWEB) , ... May 24, 2017 ... ... of the most prominent for-profit and nonprofit hospitals and health systems in the ... have turned around their institutions, led professional organizations and been instrumental in developing ...
(Date:5/24/2017)... West Orange, NJ (PRWEB) , ... May 24, 2017 , ... ... ingredients for avoiding back injury when either lifting weights for strength training and exercise ... Atlantic Spine Center . , “Body position is everything,” Dr. Chang says. “Improper ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... Population Health and Clinical Integration company, announced today that its iClinic V12.2 solution ... (PCMH) 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards which emphasize team-based ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... JERUSALEM , May 9, 2017  Oramed ... www.oramed.com ), a clinical-stage pharmaceutical company focused on ... today that the Canadian Intellectual Property Office has ... for Oral Administration of Exenatide". The patent covers ... analog. GLP-1 is an incretin hormone ...
(Date:5/8/2017)... -- MACRA replaces the outdated sustainable growth rate ... Black Book Research crowdsource-surveyed 8,845 physician practices from February ... for MIPS Compliance Technology is Booming ... or more clinicians seek to buy Merit-Based Incentive Payment ... of the changes, the hunt is on for the ...
(Date:5/6/2017)... Provista , a proven leader in the supply chain industry ... Jim Cunniff as the company,s new president and CEO. ... Provista, including most recently serving as the president and CEO ... He assumed his new role with Provista on May 1, ... says Jody Hatcher , president, Sourcing and Collaboration Services ...
Breaking Medicine Technology: